PMID: 375848Apr 1, 1979Paper

Indomethacin in rheumatoid arthritis: clinical effects, pharmacokinetics, and platelet studies in responders and nonresponders

Annals of the Rheumatic Diseases
N BaberM L Orme

Abstract

Twenty patients with definite or classical rheumatoid arthritis entered and completed a sequential study of placebo for 1 week, oral indomethacin 25 mg 3 times a day for 3 weeks, and oral indomethacin 25 mg 3 times a day plus 100 mg indomethacin suppository at night for 3 weeks. Twelve of the patients had previously been classified as responders and eight as nonresponders to indomethacin by an independent assessor. At the end of each period patients were assessed by a blind observer for duration of morning stiffness, pain score, digital joint size, grip strength, articular index, analgesic tablet usage, and the patient's own overall global assessment and comparative global assessment. In 8 of the 9 tests used responders improved on indomethacin in comparison with placebo, while nonresponders did not improve. There were no significant differences between responders and nonresponders in the plasma half-life, plasma clearance of indomethacin, protein binding of indomethacin, or urinary excretion of free or conjugated indomethacin. There were no significant differences between responders and nonresponders in the urinary excretion of 7HDPA or in the platelet aggregation or platelet malonyldialdehyde production tests. In responders t...Continue Reading

References

Sep 1, 1978·Clinical Pharmacology and Therapeutics·N BaberM L Orme
Apr 1, 1976·Southern Medical Journal·R CadeG Spooner
May 1, 1976·British Medical Journal·E C HuskissonS Franklin
Sep 1, 1975·Clinical Pharmacology and Therapeutics·G AlvánL Palmér
Jun 1, 1954·The Biochemical Journal·P TRINDER

❮ Previous
Next ❯

Citations

Jun 1, 1980·European Journal of Clinical Pharmacology·R EkstrandB Sarby
Jan 1, 1989·European Journal of Clinical Pharmacology·L O EriksonA Melander
Oct 1, 1982·European Journal of Clinical Pharmacology·K KaarelaA Gordin
Jun 1, 1985·Clinical Rheumatology·J P Famaey
Jan 1, 1987·Pharmacology & Therapeutics·R O DayJ de Jager
Jun 13, 1991·The New England Journal of Medicine·P M Brooks, R O Day
Nov 1, 1995·Clinical and Experimental Pharmacology & Physiology·J S Walker
Dec 1, 1979·Annals of the Rheumatic Diseases·M L OrmeT R Littler
Feb 5, 2014·Clinical Pharmacokinetics·Erik RyttingMahmoud S Ahmed
Jan 1, 1987·European Journal of Clinical Pharmacology·A MarzoA La Manna
Mar 30, 2007·Digestive Diseases and Sciences·Maggie LuDavid Y Graham
Jan 1, 1984·Current Medical Research and Opinion·A GordinK Holttinen
Jan 1, 1985·Current Medical Research and Opinion·A GordinJ Nuutila
Oct 20, 2006·Journal of Clinical Pharmacology·Josiane Cristófani PoggiMarina Lemos dos Reis
Oct 25, 1985·The American Journal of Medicine·K C Yeh
Aug 1, 1988·Baillière's Clinical Rheumatology·R O DayK M Williams
Jan 1, 1981·Scandinavian Journal of Rheumatology. Supplement·M OrmeT Littler
Jan 1, 1980·Scandinavian Journal of Rheumatology. Supplement·H I LundP H Petersen
Dec 1, 1979·Annals of the Rheumatic Diseases·A B Myles
May 1, 1997·Experimental Lung Research·F AziziJ H Widdicombe
Jun 1, 1987·British Journal of Clinical Pharmacology·R O Day, P M Brooks
Nov 1, 1983·Pharmacotherapy·E S Waller
Dec 1, 1984·Drug Intelligence & Clinical Pharmacy·J A Green
Jan 1, 1984·Drug Intelligence & Clinical Pharmacy·R S Porter
Jun 1, 1982·Annals of Tropical Medicine and Parasitology·K AwadziH M Gilles
Dec 1, 1986·British Journal of Clinical Pharmacology·B LundR B Andersen
Jun 30, 2021·British Journal of Clinical Pharmacology·Venkateswaran C PillaiRaman Venkataramanan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.